Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.54 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.54 |
| ▸ | NFE2 | Q16621 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1610113 | 0.94 | NPSR1 (0.52) | ALDH1A1POLBNPSR1SMN1; SMN2NTRK1 | |
| SCHEMBL1493373 | 0.94 | NPSR1 (0.55) | ALDH1A1POLBNPSR1SMN1; SMN2NTRK1 | |
| SCHEMBL1493410 | 0.92 | CYP3A4 (0.53) | ALDH1A1POLBNPSR1SMN1; SMN2NTRK1 | |
| SCHEMBL1611034 | 0.92 | KMT2A (0.56) | ALDH1A1POLBNPSR1SMN1; SMN2NTRK1 | |
| SCHEMBL1612310 | 0.90 | NPSR1 (0.51) | ALDH1A1POLBNPSR1SMN1; SMN2NTRK1 | |
| SCHEMBL1611457 | 0.90 | ALDH1A1 (0.60) | ALDH1A1POLBSMN1; SMN2NTRK1NTRK2 | |
| SCHEMBL1493481 | 0.88 | NPSR1 (0.49) | ALDH1A1POLBNPSR1SMN1; SMN2KMT2A | |
| SCHEMBL1611894 | 0.88 | ALDH1A1 (0.66) | ALDH1A1NPSR1SMN1; SMN2NTRK1NTRK2 | |
| SCHEMBL1611435 | 0.87 | NPSR1 (0.49) | ALDH1A1NPSR1SMN1; SMN2NTRK1NTRK2 | |
| SCHEMBL1611780 | 0.87 | SMN1; SMN2 (0.47) | ALDH1A1POLBNPSR1SMN1; SMN2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | ALDH1A1 3233/4885POLB 4782/4885NPSR1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.